Anzeige
Mehr »
Login
Montag, 29.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
12 Leser
Artikel bewerten:
(0)

Biliary Cirrhosis Market Pipeline H2 2015 and Obeticholic Acid Comprehensive Patent Research Reports

PUNE, India, September 8, 2015 /PRNewswire/ --

Biliary Cirrhosis - Pipeline Review, H2 2015 and Obeticholic Acid - Comprehensive patent search are the latest additions of market research reports under the disease and treatment business intelligence collection of RnRMarketResearch.com.

Complete report on Biliary Cirrhosis pipeline spread across 82 pages, talking about 11 companies, 12 drug profiles and supported with 25 tables and 14 figures is now available at http://www.rnrmarketresearch.com/biliary-cirrhosis-pipeline-review-h2-2015-market-report.html .

This report provides comprehensive information on the therapeutic development for Biliary Cirrhosis pipeline, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Biliary Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

This Biliary Cirrhosis pipeline research provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. It helps identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage and develop strategic initiatives by understanding the focus areas of leading companies. The report also assists to identify and understand important and diverse types of therapeutics under development for Biliary Cirrhosis, plan mergers and acquisitions effectively by identifying key players of the most promising pipeline as well as devise corrective measures for pipeline projects by understanding Biliary Cirrhosis pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope and modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline with the help of data and information in this Biliary Cirrhosis pipeline report.

Companies involved in Biliary Cirrhosis therapeutics development and mentioned in this research include AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., GlaxoSmithKline Plc, Intercept Pharmaceuticals, Inc., Johnson & Johnson, MediGene AG, NGM Biopharmaceuticals, Inc., Shire Plc and Virobay Inc. Drug profiles coverage include A-4250, budesonide, FFP-104, GSK-2330672, MBX-8025, NGM-282, obeticholic acid, RhuDex, SHP-625, Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis, ustekinumab and VBY-825. Order a copy of Biliary Cirrhosis - Pipeline Review, H2 2015 market research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=412977 .

Figures provided in this Biliary Cirrhosis pipeline report include:

Number of Products under Development for Biliary Cirrhosis, H2 2015

Number of Products under Development for Biliary Cirrhosis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

The second and related research titled Obeticholic Acid - Comprehensive patent search provides structured, pre-analyzed comprehensive patent data for obeticholic acid. This report covers data and information for International Nonproprietary Name: Obeticholic Acid; Indications: Treatment of primary biliary cirrhosis; Treatment of primary sclerosing cholangitis; Treatment of non-alcoholic steatohepatitis and Innovator: Intercept. The In-depth search contains patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents. In-depth search features include comprehensive patent searching, covering the world's key territories, identifies patents covering molecule, formulation, process, use, combinations and more, patent identification, categorization and interpretation and more. Grouped by patent family and assigned to development categories based on Interpretation of key aspects of the patent claims, this patent search reports offer comprehensive litigation alerts linked to patent numbers, monthly updates to patent families, statuses, and litigation clearly identified. The report enables fast analysis and verification by hyper-linking to crucial patent documents and national registers as well as offers the feature of adding own notes, save searches and results. Read more at http://www.rnrmarketresearch.com/obeticholic-acid-comprehensive-patent-search-market-report.html .

Explore more reports on the pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us:

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed


Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.